Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for hematologic disorders, with an emphasis on mutant calreticulin-driven myeloproliferative neoplasms. Its current pipeline centers on DMR-001, an investigational monoclonal antibody therapy for essential thrombocythemia, alongside DMR-002 and DMR-003, which are designed to broaden coverage across mutCALR-driven disease biology. The company also develops GB3226, a small-molecule inhibitor targeting ENL-YEATS and FLT3 for acute myeloid leukemia. Damora Therapeutics concentrates on advancing targeted, disease-modifying therapies for blood cancers and related marrow disorders through a research-driven clinical development model. Founded in 2011 and headquartered in Waltham, Massachusetts, Damora Therapeutics operates in the biopharmaceutical sector as a developer of specialized therapies for patients with significant unmet medical needs.